/l) and giant platelets were observed in the peripheral blood smear. Bleeding time (Duke's method) was mildly prolonged to 9 min (normal range, 2-5 min). vWF ristocetin cofactor activity was 92% (normal range, 60-170%). Platelet aggregation analysis could not be performed because of the unavailability of the test at our facility. Bone marrow examination performed 5 months after the first visit showed normal cellularity and no signs of dysplasia or megakaryocytosis (megakaryocytes 0.2%, 50/μl). No chromosomal abnormality was detected. Initial platelet flow cytometry (FCM) for platelet membrane glycoproteins by outsourcing showed an apparently normal percentage of positiveness as judged against the cutoff level in the negative control: GPIIb 97.4%, GPIIIa 99.0%, GPbα 95.8%, and GPIX 93.0% (data not shown). On the other hand, the results showed low mean fluorescence intensity (MFI) for GPIbα and GPIX. Repeat analysis revealed a significant decrease in MFI for GPIbα (20.0%) and GPIX (12.9%) compared with that in healthy persons. Regarding the GPIIb/IIIa analysis, the MFI was higher than the reference data that reflected the large surface area of giant platelets (278.6%; Figure 2 ). After obtaining approval from the ethical review boards of our facilities and the parents' written informed consent, we performed DNA sequencing analysis of the patient and her asymptomatic parents (Figure 1b ). All the coding exons for GP1BA, GP1BB, and GP9 were PCR amplified and directly sequenced by the Sanger method. The results showed that the patient was compound heterozygous for two missense mutations in GP9, NM_000174.3:c.182A4G and NM_000174.3:c.266G4A. Her father was a heterozygous carrier of the c.182A4G mutation, and her mother was a heterozygous carrier of the c.266G4A mutation. No mutations were found in GP1BA and GP1BB. A BSS diagnosis was genetically confirmed, and she began a monthly follow-up regime. Further, she was treated for iron-deficient anemia. Thereafter, no severe bleeding episode has occurred to date.
BSS patients have congenital defects in the GPIb-IX-V complex, a platelet receptor for vWF, and present with severe bleeding caused by defective primary hemostasis. The GPIb-IX-V complex is composed of four polypeptide subunits, GPIbα, GPIbβ, GPIX, and GPV, that belong to the leucine-rich repeat family. 5 A major ligand-binding domain exists within the N-terminal of GPIbα. With the exception of rare autosomal dominant cases, 3 the disorder is usually inherited as an autosomal recessive trait. Many of patients are homozygous for mutations in one of the three genes: GP1BA (NM_000173.5), GP1BB (NM_000407.4), and GP9 (NM_000174.3).
Since the first report by Ware et al., 6~6 0 gene mutations that include missense, deletion, nonsense, and frameshift alterations have been detected in the three culprit genes. 7 Without the concurrent expression of three genes, the GPIb-IX-V complex is not expressed efficiently on the platelet surface. 8 Our patient with a low count of giant platelets had a significantly lower MFI for GPIbα and GPIX expressions than those in normal controls (Figure 2 ). Carriers may have slightly large platelets and decreased expression of GPIb-IX-V complex expression, even though they are usually asymptomatic with a normal number of platelets. 2, 3 In this case, GP expression of the parents, as assessed by FCM, showed slightly increased GpIIb, GPIIIa, and GPIIb/IIIa complex compared with that in normal controls, which is a common finding with giant platelets with a large surface area (paternal GPIIIa expression is the exception, and it will be discussed later). GPIbα and GPIX were expressed normally on the enlarged surface, which suggests that expression per unit area of the two GPs decreased in comparison with a normal control because they are heterozygous carriers.
We identified compound heterozygous GP9 mutations in the proband that consisted of c.182A4G resulting in p.Asn61Ser (N61S) substitution and c.266G4A resulting in p.Cys89Tyr (C89Y); both are already known to be causative mutations for BSS (Figure 1b) . [9] [10] [11] [12] The former missense mutation occurs within the leucine-rich repeat motif, which disturbs the proper folding and reduces the stability of GPIX and ultimately prevents the expression of the GPIb-IX-V complex on the platelet surface. 13 The N61S mutation was first described in 1993 by Write et al. and is shared by northern and central European Populations as a founder mutation. 10, 14, 15 The patient's father, who is a heterozygous for N61S, is also heterozygous for the human platelet antigen (HPA)-1ab. This was accidentally discovered by FCM, in which decreased expression of GPIIIa and normal expression of GPIIb and GPIIb/IIIa were observed. This is because the anti-GPIIIa antibody SZ21 used in FCM recognizes the HPA-1a epitope and thus the HPA-1b is not detected. HPA-1 genotyping revealed HPA-1a/b heterozygosity in the father (data not shown). Although HPA-1a is common in Japanese and Caucasian populations, the frequency of HPA-1b is different in the two races: extremely rare in Japanese, but relatively common (10-30%) in Caucasians. 16 There is little information about the ancestors of the present case; however, it can be judged from these two facts that her father's origin was European.
In contrast, maternal C89Y substitution, first described in 1996, is thought to be the Japanese founder mutation. 11 The mutation causes a structural instability in the GPIX protein due to a substitution of cysteine necessary for intramolecular disulfide bonding of the protein. In vitro expression studies in heterologous cells implicated the mutation as the basis of BSS. 12 A detailed interview revealed that her maternal great-grandfather was a resident of Japan's Saga Prefecture and first-generation Brazilian (Figure 1a) . Since 1908, approximately 130 000 Japanese people have immigrated to Brazil, which is now home to the largest population of Japanese descent outside of Japan.
The global and long-term movement of people, accompanied by genomes, has generated novel genetic encounters between individuals of totally different origins.
In conclusion, we described a girl with BSS who is a compound heterozygote for a combination of known founder mutations. Although this is a single case study, we suggest that the genetic interchange across races may change disease epidemiology. We should diagnose and treat hereditary diseases with a wide perspective. 
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